[go: up one dir, main page]

ATE456056T1 - Methode zur bestimmung der physiologischen wirkungen von hämoglobin - Google Patents

Methode zur bestimmung der physiologischen wirkungen von hämoglobin

Info

Publication number
ATE456056T1
ATE456056T1 AT00955336T AT00955336T ATE456056T1 AT E456056 T1 ATE456056 T1 AT E456056T1 AT 00955336 T AT00955336 T AT 00955336T AT 00955336 T AT00955336 T AT 00955336T AT E456056 T1 ATE456056 T1 AT E456056T1
Authority
AT
Austria
Prior art keywords
hemoglobin
serves
red blood
determining
physiological effects
Prior art date
Application number
AT00955336T
Other languages
English (en)
Inventor
Jonathan Stamler
Andrew Gow
David Singel
Original Assignee
Univ Duke
Univ Montana Res Dev Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Univ Montana Res Dev Inst filed Critical Univ Duke
Application granted granted Critical
Publication of ATE456056T1 publication Critical patent/ATE456056T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/805—Haemoglobins; Myoglobins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00955336T 1999-08-02 2000-08-02 Methode zur bestimmung der physiologischen wirkungen von hämoglobin ATE456056T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14668099P 1999-08-02 1999-08-02
PCT/US2000/021101 WO2001009616A2 (en) 1999-08-02 2000-08-02 Method for determining physiological effects of hemoglobin

Publications (1)

Publication Number Publication Date
ATE456056T1 true ATE456056T1 (de) 2010-02-15

Family

ID=22518495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955336T ATE456056T1 (de) 1999-08-02 2000-08-02 Methode zur bestimmung der physiologischen wirkungen von hämoglobin

Country Status (7)

Country Link
US (2) US20030022267A1 (de)
EP (1) EP1204870B1 (de)
AT (1) ATE456056T1 (de)
AU (1) AU769210B2 (de)
CA (2) CA2381205C (de)
DE (1) DE60043731D1 (de)
WO (1) WO2001009616A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627738B2 (en) * 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US6197745B1 (en) 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US6855691B1 (en) 1995-09-15 2005-02-15 Duke University Methods for producing and using S-nitrosohemoglobins
US6911427B1 (en) 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
US20030059436A1 (en) * 2001-03-02 2003-03-27 St. Elizabeth's Medical Center, Inc. Band 3 antigenic peptides, malaria polypeptides and uses thereof
WO2004054433A2 (en) * 2002-12-12 2004-07-01 Duke University Forming iron nitrosyl hemoglobin
EP1648475B1 (de) 2003-07-09 2007-09-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
BRPI0705396B1 (pt) * 2007-12-12 2021-10-05 Universidade Estadual De Campinas - Unicamp Compostos derivados ftalimídicos
AU2008345034A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
DE102009053225A1 (de) * 2009-11-06 2011-05-12 Deutsche Sporthochschule Köln Verfahren zur Bestimmung der totalen Hämoglobinmenge im Körper eines Lebewesens
EP2624823A4 (de) * 2010-09-23 2016-08-03 Inflammagen Verabreichung von serinproteasehemmern in den magen
JP6389125B2 (ja) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
US11173235B2 (en) 2016-07-15 2021-11-16 Cook Regentec Llc Nitrite eluting devices and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439882A (en) * 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
ES2082732T3 (es) * 1990-12-05 1997-12-16 Gen Hospital Corp Tratamiento de la vasoconstriccion pulmonar reversible y de la broncoconstriccion.
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US6153186A (en) * 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US6916471B2 (en) * 1995-09-15 2005-07-12 Duke University Red blood cells loaded with S-nitrosothiol and uses therefor
US6911427B1 (en) * 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
US6627738B2 (en) * 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
EP1015490B1 (de) * 1997-02-06 2004-04-14 Duke University Unmodifizierte hämoglobine und deren verwendung
US6087087A (en) * 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
US6142147A (en) * 1998-03-31 2000-11-07 The General Hospital Corporation Nasal delivery system for inhaled nitric oxide

Also Published As

Publication number Publication date
AU6755600A (en) 2001-02-19
WO2001009616A3 (en) 2001-11-15
CA2381205C (en) 2010-05-11
EP1204870B1 (de) 2010-01-20
DE60043731D1 (de) 2010-03-11
US20090232909A1 (en) 2009-09-17
CA2680378C (en) 2013-09-24
CA2381205A1 (en) 2001-02-08
EP1204870A2 (de) 2002-05-15
WO2001009616A2 (en) 2001-02-08
CA2680378A1 (en) 2001-02-08
US20030022267A1 (en) 2003-01-30
AU769210B2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
DE60043731D1 (de) Methode zur bestimmung der physiologischen wirkungen von hämoglobin
Dickerson et al. Chemical changes in skeletal muscle during development
Schwartz et al. Degradation of myofibrillar proteins by cathepsins B and D
Joel Stimulation of metabolism of rat brown adipose tissue by addition of lipolytic hormones in vitro
Hermolin et al. Topology, organization, and function of the psi subunit in the F0 sector of the H+-ATPase of Escherichia coli.
FRANKLYN et al. AMIODARONE AND THYROID HORMONE ACTION JAYNE A.
Mandel et al. Insulin stimulates myogenesis in a rat myoblast line
Stromberg et al. Human term placenta contains transforming growth factors
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
Malhotra et al. Multiple cardiac contractile protein abnormalities in myopathic Syrian hamsters (BIO 53: 58)
Brion et al. Deficiency of cyclic AMP-dependent protein kinases in human psoriasis.
Miller et al. Utilization of L-methionine sulfoxide by the rat
Coronel et al. Catalytic properties of the sperm‐specific lactate dehydrogenase (LDH X or C4) from different species
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
WO2002075302A8 (en) Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
Hanson et al. Immune electrophoretic analysis of bovine milk and purified bovine milk protein fractions
Loven et al. Transformation affects superoxide dismutase activity
McArdle et al. Ca2+-uptake by tissue sections and biochemical characteristics of sarcoplasmic reticulum isolated from fish fast and slow muscles
Pandey et al. Circadian rhythms of serotonin and the electrical activity of the frontal ganglion of the cockroach, Periplaneta americana
KATO et al. Induction of S100 protein in 3T3‐L1 cells during differentiation to adipocytes and its liberating by lipolytic hormones
DE69332373D1 (de) Menschlicher epidermaler Gen-Promotor
von Wyl Paragonial proteins of Drosophila melanogaster adult male: electrophoretic separation and molecular weight estimation
Orozco et al. A description of the basic system of components in pregnant mice sera responsible for'early pregnancy factor'activity
Kim et al. Secretory protein synthesis in parotid glands of young and old rats

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties